GLPG
Galapagos NV
$27.73
-3.75%
2026-05-07
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Key Fundamentals
P/E Ratio
3.19
Forward P/E
-17.34
EPS (TTM)
$8.68
ROE
16.3%
Revenue Growth (YoY)
-91.4%
Profit Margin
46.8%
Debt/Equity
0.20
Price/Book
9.57
Market Cap
$1.86B
Avg Volume (10D)
167K
Recent Breakout Signals
No recent breakout signals detected for GLPG.
Recent Price Range (60 Days)
60D High
$36.24
60D Low
$27.16
Avg Volume
155K
Latest Close
$27.73
Get breakout alerts for GLPG
Sign up for Breakout Scanner to receive daily notifications when GLPG triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Galapagos NV (GLPG) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GLPG daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GLPG operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.